AT THE HEART OF IMPROVED CARDIOVASCULAR OUTCOMES

COMPANY OVERVIEW

NASDAQ: AMRN | JULY 2026

AMARIN®

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, guidance, and other statements. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation.

Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

A Message from our President & CEO

Aaron Berg, President & CEO

"Our results for Q2 2026 marked an inflection point in our evolution, demonstrating that the decisions we have made are translating into stronger execution, a scalable business model, and a path towards sustainable growth and profitability.

We are seeing a promising early-stage international sales trajectory in a number of markets where there remains significant unmet need, while preserving a leading U.S. presence for VASCEPA®.

We are supporting these commercial trends with a strong financial foundation, including a growing cash position and no debt.

As our work continues, we are confident in the significant opportunities that lie ahead to improve patient outcomes globally and create meaningful long-term value for our shareholders."

Who We Are: An Established Leader in Cardiovascular Therapeutics

- **First and only FDA-approved** oral therapy to reduce cardiovascular (CV) risk when added to recommended statin therapy.
- 2018 groundbreaking clinical study[1] proved that VASCEPA® (icosapent ethyl or IPE) **lowers the chance of a major adverse, life-threatening CV event** (such as a heart attack or stroke) by **25%**[2] when added to a statin.[3]
- **Expanding evidence base continues to support IPE's role in CV risk reduction**, with continued recognition from medical societies worldwide and inclusion in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline[4] and the AHA/ACC/Multisociety Guideline on Cardiovascular-Kidney-Metabolic Syndrome[5], **reinforcing IPE's relevance** for millions living with persistent cardiovascular risk.

$3.5B
CUMULATIVE SALES SINCE LAUNCH IN 2013

31M+
PRESCRIPTIONS WRITTEN IN U.S. SINCE LAUNCH IN 2013

>271K
U.S. PRESCRIBERS

25%
RELATIVE RISK REDUCTION FOR CV EVENTS ON TOP OF STATIN THERAPY[3]

50+
COUNTRIES WITH CVRR APPROVALS[6]

CVRR = Cardiovascular Risk Reduction

70+
MEDICAL SOCIETY RECOGNITIONS GLOBALLY[6,7]

500+
SCIENTIFIC PUBLICATIONS VALIDATING THE SCIENCE

1. REDUCE-IT® study *N Engl J Med.* 2019; 380 (1): 11-22, 2. In adults on maximally tolerated statins with TG≥ 150 mg/dL and established CVD or diabetes and ≥ 2 CVD risk factors, 3. In a clinical study, patients treated with VASCEPA and a statin had fewer cardiovascular (CV) events (17.2%) compared to those who took a placebo (22%), 4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2026 Mar 13:S0735-1097(25)10254-4. doi: 10.1016/j.jacc.2025.11.016. Epub ahead of print, 5. Ndumele, Chiadi E., et al. "2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." *Circulation*, 9 June 2026, https://doi.org/10.1161/cir.0000000000001453, 6. Data on File, 7.Miller M, Tokgozoglu L, Parhofer KG, et al. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. *Expert Rev Cardiovasc Ther.* 2022;20(8):609-625.

Data as of 6/30/2026

Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position; Poised for Long-Term Growth

- **Transformed international commercial strategy;** fully partnered across nearly 100 countries; strategic emphasis on Europe supported by intellectual property protection through 2039.
- **Restructuring initiatives completed,** resulting in a leaner, more focused operating model.
- **Established global partnership network** with multiple long-duration revenue streams including royalties, product supply revenue, and milestone payments.
- **Large and growing global market opportunity,** ~ 640 M people living with cardiovascular disease (CVD) worldwide.
- **VASCEPA®/VAZKEPA® (icosapent ethyl or IPE):**
  - U.S.: Leading share of IPE prescriptions, 5 years post generic entry; source of continued revenue and cash flow.
  - International: 7 strategic partnerships well-positioned to expand patient access, accelerate commercialization, and maximize the brand's global potential.
- **Growing Cash Position, No Debt**
- **Focused on sustainable value creation** through operational efficiency, global commercial expansion, and disciplined capital allocation.

DUBLIN, IRELAND (IRELAND TAX DOMICILE)
HQ: **BRIDGEWATER**, NJ

$315 M CASH

20+ M ADR SHARES OUTSTANDING

$0 DEBT

$1 BN NOLs

CASH FLOW (expect to generate positive cash flow for FY 2026)

Financial data as of 6/30/2026

Our Financials: Executing a More Efficient Operating Model to Support Future Global Growth

Key Takeaways:

- ☑ Q2 2026 Results Highlighted by Improved European Sales from Q1 2026, Lower Operating Expenses, and Higher Cash Position
- ☑ Q2 2026 net product revenue of $39.1 M
- ☑ Restructuring Now Complete; ~ $70 M of OPEX savings has established new expense baseline
- ☑ Cash flow positive; expect to generate positive cash flow for FY 2026
- ☑ $314.6 M in aggregate cash and investments; no long-term debt

Operating Results:

($ in M)	Q2 26	Q2 25	Change
Product Net Revenue	**$39.1**	**46.6**	**(16)%**
U.S. Product NR	$32.2	36.5	(12)%
Europe Product NR	$5.4	6.6	(17)%
RoW Product NR	$1.4	3.5	(61)%
Licensing & Royalty	$3.1	26.1	(88)%
Gross Profit	**$15.0**	**50.4**	**(70)%**
% margin (Product NR)	*30%*	*52%*	*(22) Pts*
Operating Expenses	**$27.0**	**66.3**	**(59)%**
SG&A	$22.2	38.7	(43)%
R&D	$4.8	4.9	(3)%
Restructuring	--	22.8	NM
Operating Loss	**$(12.0)**	**$(16.0)**	**25%**
% margin	*(28)%*	*(22)%*	*(6) Pts*
Net Loss	**$(7.7)**	**$(14.1)**	**45%**
% margin	*(18)%*	*(19)%*	*1 Pts*

NM - Not Meaningful
** The slight decline in European revenue was attributable to moving to a partnered sales model in the second half of 2025*

Our U.S. Business: VASCEPA® Remains U.S. Market Leader Across All Available Icosapent Ethyl Products

- **Proven efficacy in CVRR**
- **Refined U.S. commercial strategy** providing efficient revenue generation and positive cash flow
- Based on early feedback, we expect to retain a significant portion of our exclusive business through the end of 2026
- **Proven complement to other cardiometabolic standard of care therapies** as shown in REDUCE-IT

U.S. Market Share of VASCEPA

FY 2024	FY 2025	Q2 2026
54.4%	48.1%	48.5%

Source: Symphony METYS, June 2026

Vascepa (icosapent ethyl)

Quarterly U.S. Prescription Growth v. Prior Year Period



Source: Symphony METYS, June 2026

Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners

Vascepa® (icosapent ethyl) Vazkepa® (icosapent ethyl)



Existing Amarin Presence

Launched

Regulatory Approval Achieved; P&R Efforts in Process

Regulatory Preparations in Process

Our International Business: Recordati Partnership Advancing VAZKEPA's European Growth Opportunity

Why We Partnered

Unlock the full European opportunity

- Exclusive long-term license covering **59 countries**
- Leverages Recordati's established cardiovascular (CV) commercial and reimbursement infrastructure
- Broader, faster market access
- Capital-efficient model preserving significant long-term economics

One Year of Progress

Execution translating into commercial momentum

✓ Dedicated CV organization established

- Expanded and deployed dedicated CV field reps across Europe
- Accelerating execution in key markets - Spain, Italy, UK

✓ Strong commercial performance

- European in-market demand increased ~**69% YoY** through May 2026, exceeding pre-licensing growth rates
- Strong and successful launch in Italy

✓ Continued market expansion

- Pricing, reimbursement and access advancing across licensed territories

Long-Term Value Creation

Amarin Future Opportunity

Favorable Economics

- **$25M** upfront payment received
- Ongoing product supply revenues
- Royalty-bearing product sales
- Up to **$150M** in commercial milestones

Growth Runway

- Europe remains a large, underpenetrated CVD market
- Partnership expands reach into more countries and primary care
- Broader commercialization increases long-term royalty and milestone potential

One year in, the partnership is delivering: accelerating commercialization, expanding patient access, and growing Amarin's long-term value opportunity.

Our International Business: Seven Partners Actively Building Market Opportunities Across Multiple Continents

7 Ex-U.S. partnerships focused on maximizing patient access to VASCEPA/ VAZKEPA – many in early commercialization stages, poised for future growth.

INTERNATIONAL PARTNERSHIPS - CURRENT PHASES

Regulatory	Pricing / Reimbursement	Commercialization
Lotus Pharmaceutical	Biologix, CSL Seqirus, EDDING 亿腾, Lotus Pharmaceutical, Recordati	Biologix, CSL Seqirus, EDDING 亿腾, HLS Therapeutics, Neopharm Consumer Products, Recordati

3 Core Phases of Partnership (overlap through various times during partnership)

Regulatory – Review / Approval / CMC / Medical / Clinical

Pricing / Reimbursement – Medical / HEOR / Supply Preparations

Commercialization – Sales Planning & Execution / Medical Education – Training – Support

Regulatory Pricing & Reimbursement:

- Working closely with our commercialization partners to advance regulatory submissions and support partners' needs through various stages of review and market launch preparations.

Commercialization:

- Preparing for early 2027 launches in **South Korea and Singapore**.
- **Commercializing across 11 countries,** 3 of which are in their first year on the market and are progressing well.
- **Realized increased year-over-year demand** in all launched markets.
- Partnerships providing **growing cash generation**.

CMC = Chemistry, Manufacturing & Controls
HEOR = Health Economics & Outcomes Research

2H 2026 Focus: Continued Execution & Driving Long-term Growth Opportunities

A **multi-pronged** and **multi-national** approach:

- **Accelerate** commercial expansion across partnered international markets to maximize patient access.
- **Sustain** U.S. leadership in the branded IPE market.
- **Maintain** disciplined financial management while identifying additional operational efficiencies.
- **Invest** astutely to enhance understanding and awareness of IPE.
- **Work** actively with exclusive financial advisor to identify value-building strategic opportunities.

Amarin Key Takeaways

HEALTHY FINANCIALS	UNTAPPED POTENTIAL	PRODUCT POWER	STRONG SCIENCE	MEDICAL ENDORSEMENT
Cash Flow EXPECT TO BE CASH FLOW POSITIVE FOR FULL YEAR 2026	**~640M** PEOPLE LIVING WITH CVD, MAKING IT THE LEADING CAUSE OF DEATH WORLDWIDE[1]	**>271K** U.S. PRESCRIBERS	**3** SUCCESSFUL PHASE 3 PIVOTAL TRIALS	**500+** SCIENTIFIC PUBLICATIONS VALIDATING THE SCIENCE
$315M CASH*	**7** PARTNERSHIPS ACROSS THE GLOBE	**31M+** PRESCRIPTIONS WRITTEN IN U.S. SINCE 2013 LAUNCH	**25%** RELATIVE RISK REDUCTION ON TOP OF STATIN THERAPY[4]	**70+** MEDICAL SOCIETY RECOGNITIONS GLOBALLY[2,3]
$0 DEBT*	**2039** EUROPEAN IP RUNWAY	**$3.5B** CUMULATIVE SALES SINCE 2013 LAUNCH	FDA APPROVED **1ST** AND ONLY FDA-APPROVED ORAL AGENT TO REDUCE CV RISK WHEN ADDED ON TOP OF RECOMMENDED STATIN THERAPY	**50+** COUNTRIES WITH CVRR[5] APPROVALS[3]

* Financials as of 6/30/26

Notes: Market data as of June 2026. 1.https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-global-factsheet.pdf, 2. Miller M, Tokgozoglu L, Parhofer KG, et al. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. *Expert Rev Cardiovasc Ther.* 2022;20(8):609-625, 3.Data on File 4. Bhatt DL, et al; for REDUCE-IT Investigators. N Engl J Med. 2019;380(1):11-22; Bhatt DL, et al. Presented at: American Heart Association Scientific Sessions; November 10-12, 2018; Chicago, IL, 5. CVRR = Cardiovascular Risk Reduction